뒤로
Urogen Pharma Ltd(URGN) 가격
URGN 주가 차트
URGN 주가 예측
Urogen Pharma Ltd
$19.33
2.81%
$0.52
종가: Jan 20, 16:00:00 GMT-5
$19.5
0.87%
$0.17
애프터마켓: Jan 20, 20:00:00 GMT-5
주요 통계
이전 종가
$18.8
시가
$18.2
일일 범위
$18.2 - $19.5
52주 범위
$3.42 - $30
거래량
560.4K
평균 거래량
998.7K
EPS(TTM)
-3.31
배당수익률
--
시가총액
$912.7M
URGN란 무엇인가요?
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).